RETIN-A
Clinical safety rating: caution
Comprehensive clinical and safety monograph for RETIN-A (RETIN-A).
Retin-A (tretinoin) binds to retinoic acid receptors (RARα, RARβ, RARγ) and retinoid X receptors (RXR), modulating gene expression involved in cell differentiation, proliferation, and inflammation. It increases epidermal turnover, reduces comedone formation, and stimulates collagen synthesis.
| Metabolism | Topical tretinoin is metabolized in the skin and systemically via hepatic cytochrome P450 enzymes (CYP2C8, CYP2C9, CYP2B6, CYP3A4) to oxidative metabolites (e.g., 4-oxo-retinoic acid), which are further conjugated and excreted in urine and bile. |
| Excretion | After topical application, systemic absorption is minimal. The absorbed fraction is metabolized in the liver via cytochrome P450 enzymes and excreted in bile and urine as glucuronide conjugates. Renal excretion accounts for <1% of the applied dose; fecal excretion of metabolites is the primary route (<5% of applied dose). |
| Half-life | Terminal elimination half-life is approximately 0.5-2 hours for the parent drug. Clinical context: Due to rapid clearance, systemic accumulation is negligible with topical use; effects persist due to retinoid-induced gene expression changes. |
| Protein binding | Greater than 95% bound, primarily to albumin (≈90%) and lipoproteins (≈10%). |
| Volume of Distribution | When absorbed systemically, Vd is approximately 1-2 L/kg, indicating extensive tissue distribution, though systemic exposure is negligible with topical use. |
| Bioavailability | Topical: Systemic bioavailability is <1% of the applied dose (range 0.5-5% depending on formulation and skin condition). Oral: Not applicable (not administered orally). |
| Onset of Action | Topical: Clinical improvement in acne vulgaris is typically observed within 2-4 weeks of daily application. Full therapeutic effect may require 8-12 weeks. |
| Duration of Action | Effects persist for weeks after discontinuation due to alterations in gene expression and cell turnover. Clinical improvement lasts as long as treatment continues; after stopping, effects gradually wane over 4-8 weeks. |
Apply a thin layer to affected areas once daily at bedtime. Initial concentration typically 0.025% cream or 0.01% gel; titrate based on tolerability.
| Dosage form | SWAB |
| Renal impairment | No specific renal dose adjustment required; systemic absorption is minimal after topical application. |
| Liver impairment | No specific hepatic dose adjustment required; avoid use in severe hepatic impairment due to potential accumulation of excipients. |
| Pediatric use | Not recommended for use in children younger than 12 years of age due to lack of safety and efficacy data. For adolescents 12 years and older, use same as adult dosing. |
| Geriatric use | Use with caution; skin may be more sensitive. Consider lower strength (e.g., 0.025% cream) and monitor for irritation. Avoid excessive application. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for RETIN-A (RETIN-A).
| Breastfeeding | It is not known whether tretinoin is excreted in human milk after topical application. Due to the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. M/P ratio is unavailable. |
| Teratogenic Risk | Retin-A (tretinoin) is FDA Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Oral tretinoin is known to be teratogenic in humans; however, topical application is associated with minimal systemic absorption (<10%). Case reports have not demonstrated an increased risk of major birth defects with topical use, but the theoretical risk remains. Caution is advised, and use during pregnancy should be avoided unless clearly needed. |
■ FDA Black Box Warning
No FDA black box warnings for topical tretinoin. However, systemic retinoids (e.g., isotretinoin) carry warnings for teratogenicity and depression.
| Serious Effects |
["Hypersensitivity to tretinoin or any component of the formulation","Acute sunburn or eczematous skin","Concurrent use of topical products with strong drying or irritant effects (e.g., benzoyl peroxide, salicylic acid, astringents)","Pregnancy (relative contraindication; limited systemic absorption suggests low risk, but caution advised)"]
| Precautions | ["Increased sensitivity to sunlight; avoid prolonged sun exposure and use sunscreen","Initial exacerbation of acne (retinoid flare) may occur","Avoid application on eczematous, sunburned, or irritated skin","Use with caution in patients with eczema or chronic skin conditions","Not for use in pregnant women (Pregnancy Category C); potential teratogenicity if significant systemic absorption"] |
Loading safety data…
| Fetal Monitoring | No specific maternal or fetal monitoring is required beyond routine prenatal care, as systemic exposure from topical tretinoin is minimal. However, if used inadvertently during pregnancy, ultrasound monitoring for fetal anomalies may be considered. |
| Fertility Effects | No significant effects on fertility have been reported with topical tretinoin. Systemic retinoids can affect spermatogenesis and ovulation, but topical use is unlikely to have an impact due to low absorption. |